Related Experiment Videos
Summary
Flunarizine and Verapamil readily cross the placenta, accumulating in placental tissue. These calcium antagonists stimulate placental beta-human chorionic gonadotropin (β-hCG) synthesis without altering placental metabolism.
Area of Science:
- Pharmacology
- Reproductive Biology
- Toxicology
Background:
- Calcium antagonists like Flunarizine and Verapamil are used clinically.
- Understanding their placental transfer and effects is crucial for fetal safety.
- Limited data exists on the placental transfer and metabolic impact of these specific agents.
Purpose of the Study:
- To investigate the placental transfer kinetics of Flunarizine and Verapamil.
- To assess the impact of Flunarizine and Verapamil on human placental metabolism.
- To evaluate the effects of these calcium antagonists on placental hormone synthesis.
Main Methods:
- Dual in vitro perfusion of human placental lobules.
- Perfusion with Flunarizine or Verapamil (10 µg/ml) for 6 hours.
- Measurement of placental transfer, tissue accumulation, and metabolic markers (glucose consumption, lactate production, β-hCG synthesis).
Main Results:
- Flunarizine and Verapamil rapidly crossed the placental barrier but were significantly accumulated in placental tissue.
- Verapamil exhibited a higher placental transfer rate compared to Flunarizine.
- Neither drug altered placental glucose consumption or lactate production.
- Both Flunarizine and Verapamil stimulated placental beta-human chorionic gonadotropin (β-hCG) synthesis into the maternal circulation.
Conclusions:
- Flunarizine and Verapamil demonstrate significant placental transfer and accumulation.
- These calcium antagonists do not adversely affect key placental metabolic functions.
- Stimulation of placental β-hCG synthesis warrants further investigation regarding potential endocrine effects.